Abstract:Background: Vincristine is a potent therapeutic agent with well-defined activity against hematologic malignancies and solid tumors. It is a cell-cycle specific drug with concentration and exposure duration dependent activity. When used by liposomal delivery, it exhibits enhanced anti-tumor activity. However, vincristine liposome formulation in the clinic is supplied as a 3-vial-kit due to lacking sufficient stability. So it has to be prepared in situ prior to use through a multi-step process. Purpose: The purpose here is to develop a more stable and ready-to-use liposomal formulation for vincritstine in one vial. Patients and methods: A series of preparations were investigated based on sphingomyelin/cholesterol/PEG2000-DSPE lipid composition, with different drug/lipid (D/L) ratios (1/10, 1/5, 1/2), using an active sucrose octasulfate triethylamine salt gradient loading method. In this work, compared to generic vincristine sulfate liposome injection (GVM), the stability both in vivo and in vitro and efficacy in vivo of novel vincristine liposomes were investigated. Results: It was shown that the degradation of vincristine during 2-8°C storage was significantly decreased from 8.2% in 1 month (GVM) to 2.9% in 12 months (D/L ratio 1/5). The half-time for sphingomyelin/cholesterol/PEG2000-DSPE liposomes in vivo could be adjusted from 17.4 h (D/L ratio 1/10) to 22.7 h (D/L ratio 1/2) in rats, while the half-time for GVM was only 11.1 h. The increase in drug retention contributed to the lower in vivo toxicity. The antitumor efficacy was evaluated using a human melanoma tumor model and showed remarkable improvement compared to GVM. Conclusion: The study demonstrates that the new formulation with the drug/lipid ratio of 1/5 owns a higher encapsulation efficiency, better stability, lower toxicity and superior antitumor efficacy, which is screened out for further development.

Vincristine-doxorubicin co-loaded artificial low-density lipoproteins towards solid tumours

Vincristine liposomes with smaller particle size have stronger diffusion ability in tumor and improve tumor accumulation of vincristine significantly

Preparation and evaluation of doxorubicin-luminespib co-loaded multivesicular liposomes

[Cationic Liposomes Loaded with Doxorubicin Targeting to the Tumor Neovasculature in Vitro].

Co-Delivery of Doxorubicin and Plasmid by A Novel Fgfr-Mediated Cationic Liposome

[Transdermal and Lymph Targeting Transfersomes of Vincristine].

Intracellular delivery of doxorubicin with RGD-modified sterically stabilized liposomes for an improved antitumor efficacy:In vitro andin vivo

The in Vitro Cytotoxicity and in Vivo Toxicity of Doxorubicin Antiresistant Stealth Liposomes

Enhanced intracellular delivery and improved antitumor efficacy of doxorubicin by sterically stabilized liposomes modified with a synthetic RGD mimetic.

A tumor environment responsive doxorubicin-loaded nanoparticle for targeted cancer therapy.

Pharmacokinetics of intravenously administered stealth liposomal doxorubicin modulated with verapamil in rats.

Targeted delivery of RGD-modified liposomes encapsulating both combretastatin A-4 and doxorubicin for tumor therapy: in vitro and in vivo studies.

Long-circulating doxorubicin and schizandrin A liposome with drug-resistant liver cancer activity: preparation, characterization, and pharmacokinetic

Biodegradable Self-Assembled Micelles Based on MPEG-PTMC Copolymers: An Ideal Drug Delivery System for Vincristine

Increased Delivery of Doxorubicin into Tumor Cells Using Extracellularly Activated Tat Functionalized Liposomes: in Vitro and in Vivo Study

Development of a stable single-vial liposomal formulation for vincristine

Highly Biocompatible Functionalized Layer‐by‐Layer Ginger Lipid Nano Vectors Targeting P‐Selectin for Delivery of Doxorubicin to Treat Colon Cancer

Enhanced Intracellular Uptake of Sterically Stabilized Liposomal Doxorubicin in Vitro Resulting in Improved Antitumor Activity in Vivo

Recombinant lipoproteins reinforce cytotoxicity of doxorubicin to hepatocellular carcinoma.

Delivery of vincristine sulfate-conjugated gold nanoparticles using liposomes: a light-responsive nanocarrier with enhanced antitumor efficiency

Dual-modified liposome codelivery of doxorubicin and vincristine improve targeting and therapeutic efficacy of glioma